Pfizer Inc. (PFE)
Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion
The company anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86.
Pfizer forecasts 2025 profit in line with expectations
Drugmaker Pfizer on Tuesday said it was expecting its 2025 profits to be nearly in line with Wall Street expectations as it seeks to fend off criticism over its turnaround strategy from activist hedge fund Starboard Value.
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
Pfizer Inc. PFE will conduct an investor call on Tuesday to provide full-year 2025 financial guidance.
Pfizer: Lowest Levels In A Decade Is An Opportunity With A Dividend Yield Exceeding 6.5%
Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling value play. Despite revenue declines and potential regulatory risks, Pfizer remains a cash-generating machine with strong liquidity and a robust drug pipeline. Pfizer's operational improvements, debt reduction, and consistent dividend growth signal a turnaround, making it an attractive investment at current depressed levels.
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies generally see at least stability in revenue.
Pfizer: Irrational Anti-Vaccine Fear
Pfizer's stock has become appealing due to irrational vaccine fears. Market fears about RFK Jr.'s potential anti-vaccine stance are likely overblown, as neither he nor Trump have indicated plans to block vaccines. Pfizer's strong growth in oncology and specialty care, along with cost-cutting measures, suggest the stock is undervalued at below 10x EPS guidance.
Is Pfizer a Millionaire Maker?
With a market capitalization of more than $143 billion today, Pfizer (PFE 0.83%) stock won't make anyone into a millionaire unless they're willing to commit a large amount of capital and then hold the stock for a very long period of time, reinvesting all the dividends they receive along the way. Big pharma businesses simply don't grow quickly enough to deliver investors the massive returns that are necessary to generate millions from a humble starting sum.
Reader Mailbag: Is Pfizer (PFE) a Good Deal Right Now?
November was an interesting month for pharmaceutical companies in general. President-elect Trump officially announced that Robert F.
Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Pfizer (PFE) closed at $25.23, marking a -1.33% move from the previous day.
Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns
Pfizer's share price struggles despite a strong asset portfolio and $10 billion annual R&D investment, with significant Seagen acquisition integration ongoing. Q3 2024 results show 32% YoY revenue increase, driven by COVID-19 products and 14% growth excluding one-time impacts, with improved margins. Oncology revenue up 31% YoY, promising pipeline advancements, and strong vaccine portfolio, including potential Lyme disease vaccine and promising Cachexia treatment.
Pfizer Stock: A Golden Buying Opportunity (Rating Upgrade)
I upgrade Pfizer to "Strong Buy" due to its undervaluation, strong pipeline, and operational growth despite recent stock price declines. Pfizer's Q3 FY2024 earnings showed significant revenue and EPS growth, driven by COVID-19 therapies and oncology products, indicating robust strategic execution. The company's diversified portfolio, including successful vaccines and promising new drugs, positions it for long-term success and potential stock price re-rating.
PFE or NVO: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?
